Vivus acquires topiramate patents from Janssen

USA-based pharma company Vivus (Nasdaq: VVUS) has acquired a group of patents from Johnson & Johnson’s (NYSE: JNJ) Janssen Pharmaceuticals for uses of topiramate. Patents for the anticonvulsant include its use as a monotherapy and in combination with other drugs.

Johnson & Johnson markets the compound as Topamax, and is an ingredient in Vivus’ Qsymia (topiramate/phentermine), a weight-loss drug. The patents are directed to methods of the use of topiramate in treating obesity, lower blood pressure and lipid parameters and in the reduction of blood glucose. Vivus has also assumed all rights which covers topiramate use in impulse-control disorders, and will be responsible for all future financial obligations under that license.

Neither party has stated the terms of the purchase but Vivus has indicated that it will pay a one-off fee to Johnson & Johnson, which is eligible for royalties on Qsymia sales ‘for an assignment of these topiramate-related patents owned by Janssen.’ An option also exists for Vivus to buy Janssen’s royalty for a pre-established amount.